Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136170603> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W3136170603 endingPage "393" @default.
- W3136170603 startingPage "387" @default.
- W3136170603 abstract "Abstract Nivolumab plus ipilimumab (nivo/ipi) is an approved therapy for patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma (mRCC). Clinical factors that guide the selection of this regimen for patients with mRCC are urgently needed. We retrospectively analyzed medical records of patients with mRCC who were hospitalized at MD Anderson Cancer Center because of cancer‐related symptoms and received their first cycle of nivo/ipi in the inpatient setting. Clinical parameters, including demographics, histology, clinical history, response, and survival, were collected. The 4‐month survival probability, progression‐free survival (PFS), and overall survival (OS) were calculated using Kaplan‐Meier methods. Between November 2017 and 21 June 2020 patients were identified that fit the search: 19 patients (91%) had poor‐risk disease based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score; 17 patients (81%) had ≥4 risk factors; and 9 patients (43%) had sarcomatoid features on histology. Shortness of breath (28%) and abdominal pain (19%) were the two most common reasons for hospitalization. Partial response was achieved in 14% (3/21) of patients. Median PFS for all patients was 1.7 months (95% CI 0‐3.9); median OS for all patients was 1.7 months (95% CI 0‐4.2); and the 4‐month survival probability was 36% (95% CI 25%‐47%). In this retrospective study, patients with intermediate‐risk or poor‐risk mRCC who are hospitalized at a large tertiary referral center for cancer‐related symptoms derive limited clinical benefit from nivo/ipi when started in the inpatient setting. Alternative, more effective systemic therapies should be considered for these patients." @default.
- W3136170603 created "2021-03-29" @default.
- W3136170603 creator A5003873827 @default.
- W3136170603 creator A5008861348 @default.
- W3136170603 creator A5009171545 @default.
- W3136170603 creator A5013244136 @default.
- W3136170603 creator A5017490262 @default.
- W3136170603 creator A5048915309 @default.
- W3136170603 creator A5051588487 @default.
- W3136170603 creator A5058115259 @default.
- W3136170603 creator A5062684149 @default.
- W3136170603 creator A5069915515 @default.
- W3136170603 creator A5080220488 @default.
- W3136170603 date "2021-03-24" @default.
- W3136170603 modified "2023-10-14" @default.
- W3136170603 title "Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The <scp>MD</scp> Anderson Cancer Center experience" @default.
- W3136170603 cites W2099752220 @default.
- W3136170603 cites W2115108310 @default.
- W3136170603 cites W2167127503 @default.
- W3136170603 cites W2181830444 @default.
- W3136170603 cites W2544295368 @default.
- W3136170603 cites W2792937256 @default.
- W3136170603 cites W2911812451 @default.
- W3136170603 cites W2913745075 @default.
- W3136170603 cites W2947020554 @default.
- W3136170603 cites W2947589787 @default.
- W3136170603 cites W2967350775 @default.
- W3136170603 cites W2985979810 @default.
- W3136170603 cites W2991737181 @default.
- W3136170603 cites W3000381174 @default.
- W3136170603 cites W3030603071 @default.
- W3136170603 cites W3042095160 @default.
- W3136170603 cites W3056885861 @default.
- W3136170603 cites W3081958456 @default.
- W3136170603 cites W3087337028 @default.
- W3136170603 cites W3088188638 @default.
- W3136170603 doi "https://doi.org/10.1002/ijc.33560" @default.
- W3136170603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33739450" @default.
- W3136170603 hasPublicationYear "2021" @default.
- W3136170603 type Work @default.
- W3136170603 sameAs 3136170603 @default.
- W3136170603 citedByCount "6" @default.
- W3136170603 countsByYear W31361706032021 @default.
- W3136170603 countsByYear W31361706032022 @default.
- W3136170603 crossrefType "journal-article" @default.
- W3136170603 hasAuthorship W3136170603A5003873827 @default.
- W3136170603 hasAuthorship W3136170603A5008861348 @default.
- W3136170603 hasAuthorship W3136170603A5009171545 @default.
- W3136170603 hasAuthorship W3136170603A5013244136 @default.
- W3136170603 hasAuthorship W3136170603A5017490262 @default.
- W3136170603 hasAuthorship W3136170603A5048915309 @default.
- W3136170603 hasAuthorship W3136170603A5051588487 @default.
- W3136170603 hasAuthorship W3136170603A5058115259 @default.
- W3136170603 hasAuthorship W3136170603A5062684149 @default.
- W3136170603 hasAuthorship W3136170603A5069915515 @default.
- W3136170603 hasAuthorship W3136170603A5080220488 @default.
- W3136170603 hasBestOaLocation W31361706031 @default.
- W3136170603 hasConcept C121608353 @default.
- W3136170603 hasConcept C126322002 @default.
- W3136170603 hasConcept C143998085 @default.
- W3136170603 hasConcept C167135981 @default.
- W3136170603 hasConcept C2777472916 @default.
- W3136170603 hasConcept C2777701055 @default.
- W3136170603 hasConcept C2780030458 @default.
- W3136170603 hasConcept C2781068499 @default.
- W3136170603 hasConcept C2781413609 @default.
- W3136170603 hasConcept C2781433595 @default.
- W3136170603 hasConcept C71924100 @default.
- W3136170603 hasConceptScore W3136170603C121608353 @default.
- W3136170603 hasConceptScore W3136170603C126322002 @default.
- W3136170603 hasConceptScore W3136170603C143998085 @default.
- W3136170603 hasConceptScore W3136170603C167135981 @default.
- W3136170603 hasConceptScore W3136170603C2777472916 @default.
- W3136170603 hasConceptScore W3136170603C2777701055 @default.
- W3136170603 hasConceptScore W3136170603C2780030458 @default.
- W3136170603 hasConceptScore W3136170603C2781068499 @default.
- W3136170603 hasConceptScore W3136170603C2781413609 @default.
- W3136170603 hasConceptScore W3136170603C2781433595 @default.
- W3136170603 hasConceptScore W3136170603C71924100 @default.
- W3136170603 hasIssue "2" @default.
- W3136170603 hasLocation W31361706031 @default.
- W3136170603 hasOpenAccess W3136170603 @default.
- W3136170603 hasPrimaryLocation W31361706031 @default.
- W3136170603 hasRelatedWork W2804329561 @default.
- W3136170603 hasRelatedWork W2969738919 @default.
- W3136170603 hasRelatedWork W2991737181 @default.
- W3136170603 hasRelatedWork W3152520552 @default.
- W3136170603 hasRelatedWork W4205130032 @default.
- W3136170603 hasRelatedWork W4226128801 @default.
- W3136170603 hasRelatedWork W4283731517 @default.
- W3136170603 hasRelatedWork W4308054600 @default.
- W3136170603 hasRelatedWork W4310753273 @default.
- W3136170603 hasRelatedWork W4362587156 @default.
- W3136170603 hasVolume "149" @default.
- W3136170603 isParatext "false" @default.
- W3136170603 isRetracted "false" @default.
- W3136170603 magId "3136170603" @default.
- W3136170603 workType "article" @default.